Reviewed By
	Donald Farquhar , MD, FRCPC
	David R. Dixon , MD, MCISc (FM), CCFP
	National Education Committee, The University of Western Ontario

Prepared By
	Jennifer Blake , MD, MSc
Reviewed By
	Vivien Brown , MDCM, CCFP, FCFP
	Michael Boivin , B.Sc.Phm.
	Joan Bratty , MD
	Dianne Delva , MD, FCFP
	John Rowen , MD
	Catherine Wilkie , BSc, MD, CCFP, FCFP
	Wendy McCrady , BScN, MScN , RN(EC)/NP

Prepared By
	Sheldon Spier , MD, FRCP(C)
Reviewed By
	Paolo Renzi , MD, FRCPC
	Alan Kaplan , MD
	Jacques Bouchard , MD
	Robert Hauptman , MD
	Gordon Dyck , MD
	Robert Woodland , MD

Reviewed By
	R.G. Josse , MD, FRCPC
	Shawn Davison , PhD
	Angela Cheung , MD, PhD, FRCPC, CCD
	Christopher Kovacs , MD, FRCPC, FACP
	Elizabeth Shane , MD
	Aliya Khan , MD, FRCPC, FACP, FACE
	Rick Adachi , MD, FRCPC

Prepared By
	Alan Ableson , MD, CCFP, FCFP
	John Axler , MD, CCFP

Prepared By
	Lorne Gula
Reviewed By
	Evan Lockwood
	Martin J. Gardiner
	Laurent Macle

Reviewed By
	François Boucher , MD, FRCPC
	James Kellner , MD
	Nandini Sathi , MD, CCFP
	Phyllis Bedder , MD
	Lydia Hatcher , MD, CCFP, FCFP
	Carol McConnery , MD
	Bruce H. Wheeler , MD, CCFP

Reviewed By
	Serge Marchand , PhD

Reviewed By
	Anjli Acharya , B.Sc.Phm., R.Ph., CTH
	Milena Kudus , B.Sc.Phm., R.Ph., CTH
	Stephanie Young , RN

Optimizing Care in Paediatric Asthma(En Francais)

Learning Objectives

• Diagnose paediatric asthma based on asthma phenotype.
• Discuss common asthma triggers and avoidance strategies in the management of your paediatric asthma patients.
• Apply Canadian paediatric guideline based treatment strategies for your paediatric asthma patients.
• Address common parent concerns regarding the treatment of asthma including adherence and adverse effects.
• Work with your patients and their parents to develop an asthma management strategy.

St. Michael’s Hospital Osteoporosis Outreach Program 2009

Learning Objective:
Our goal is to provide up-to-date, evidence-based, scientifically sound, useful and practical information for specialists on different aspects of metabolic bone disease focusing on osteoporosis. Each individual presentation has established learning objectives.

Occupational and Environmental Cancer: Recognition and Prevention

Learning Objectives

• Name common types of occupational and environmental cancer.
• Describe how carcinogens are identified.
• Find and use published lists of carcinogens.
• Take and interpret an exposure history.
• Identify steps to take if an occupational or environmental cancer is suspected or your patient is being exposed to a carcinogen.
• Assess a cancer cluster report.
• Apply the recognition process to other occupational and environmental diseases.

Diffuse Pain in Fibromyalgia: From Neurophysiology to Clinical Observation

Learning Objectives

Patients suffering from fibromyalgia present diffuse pain symptoms that are not characteristic of neurogenic pain. However, some neurophysiological mechanisms, such as a disturbance of endogenous pain modulation systems may help understanding the mechanisms implicated. During this talk I will introduce some our work on different factors that are affecting the efficacy of these endogenous pain modulation mechanisms and discuss how diffuse pain may result from a central imbalance in endogenous excitatory and inhibitory mechanisms. Recent data will be presented supporting our understanding of the neurophysiological mechanisms of diffuse pain in fibromyalgia with some references to the clinical signs observed in the fibromyalgia patients.

Travel Medicines- A Focus on Malaria and Hepatitis A and B(En Francais)

Learning Objectives

• The basic risk factors, etiology, and clinical presentation of hepatitis A, hepatitis B and malaria.
• The geographical risk areas for hepatitis A, hepatitis B, and malaria, including areas of antimalarial drug resistance.
• Personal protective measures important for the prevention of hepatitis A, hepatitis B and malaria.
• Key considerations when vaccinating against hepatitis A and hepatitis B and how to manage non-responders.
• Key differences between available anti-malarial agents, their adverse effects, contraindications, and costs.
• Key considerations in special populations including pregnant or lactating women, children, immune compromised patients, and non-compliant patients.